2020
- 2020.08
- NovIB (inflammatory bowel disease medication) related CZ inflammatory bowel disease treatment and prevention patent application in the US
- NovDB2 (type 2 diabetes medication) related CZ compound medication patent application in Hong Kong
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 2 application in Korea
- 2020.07
- NovFS (pulmonary and hepatic fibrosis medication) related C01 fibrosis prevention and improvement patent registration in Korea
- NovRF (retroperitoneal fibrosis medication) related C01 retroperitoneal fibrosis prevention and treatment patent registration in Korea (patent co-owner: NovMetaPharma, Seoul National University Hospital, and Seoul National University Academic-Industrial Cooperation Foundation)
- International application for NovCO (cognitive impairment medication) related cognitive impairment prevention and improvement patent
- International application for NovHO (bone loss disease medication) related osteoporosis patent
- 2020.06
- C01 medication-related C01-H substance patent registration in the US
- CIP application for C01 medication-related C01-H substance patent in the US
- Nov19 (viral disease medication) related antiviral patent application in the US
- NovDB2 (type 2 diabetes medication) related C01 diabetes dosage patent application in the US
- NovOS (bone loss disease medication) related C01 osteoporosis patent application in Europe
- 2020.05
- NovOS (bone loss disease medication) related C01 osteoporosis compound medication patent registration in Korea
- NovDB2 (type 2 diabetes medication) related CZ compound medication patent application in Europe
- Divisional application for NovRD (liver and kidney medication) related C01 cell protection patent in Japan
- NovOS (bone loss disease medication) related C01 osteoporosis patent applications in 3 countries including the US, China, and Japan
- International application for NovOS (bone loss disease medication) related C01 osteoporosis compound medication patent
- 2020.04
- NovDB2 (type 2 diabetes medication) related CZ compound medication patent applications in 3 countries including the US, China, and Japan
- NovBH (antithrombotic and female menopause medication) related antithrombotic patent applications in 4 countries including the US, Europe, China, and Japan (joint application: NovMetaPharma and National Development Institute of Korean Medicine)
- International application for NovAS (vascular disease medication) related arteriosclerosis patent (joint application: NovMetaPharma and US Department of Veterans Affairs)
- 2020.03
- Domestic and international patent application for NovFS (pulmonary and hepatic fibrosis medication) related C01 fibrosis prevention and improvement patent
- Domestic and international patent application for NovRF (retroperitoneal fibrosis medication) related C01 retroperitoneal fibrosis prevention and treatment patent
- NovBP (vascular disease medication) related C01 blood pressure drop patent application in Korea (joint application: NovMetaPharma, Seoul National University Hospital, and Seoul National University Academic-Industrial Cooperation Foundation)
2019
- 2019.12
- NovAQ (type 2 diabetes medication) related AQ single medication patent registration in Japan (patent co-owner: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2019.11
- NovWH (antithrombotic and female menopause medication) related female menopause patent registration in Korea (patent co-owner: NovMetaPharma and National Development Institute of Korean Medicine)
- International application for NovOB (anti-obesity medication) related C01 obesity dosage patent
- 2019.10
- NovBH (antithrombotic and female menopause medication) related antithrombotic patent registration in Korea (patent co-owner: NovMetaPharma and National Development Institute of Korean Medicine)
- 2019.08
- Technology Evaluation: NICE D&B: A
- Korea Technology Finance Corporation: BBB
- NovRD (liver and kidney medication) related C01 cell protection patent registration in Korea
- Divisional application for NovRD (liver and kidney medication) related CHP cell protection patent in Korea
- 2019.07
- Investment attraction (total of 6 billion)
- NovHO (bone loss disease medication) related osteoporosis patent application in Korea
- 2019.06
- NovDB2 (type 2 diabetes medication) clinical phase 2b medication completed (USA)
- Started GMP batch production of substances, NovMetaPharma’s core substance technology
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 1 application in Hong Kong (joint application: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- C01 based medication-related C01-H substance patent application in the US
- 2019.05
- Investment attraction (total of 700 million)
- NovOS (bone loss disease medication) related C01 osteoporosis compound medication patent application in Korea
- 2019.04
- Investment attraction (total of 4.5 billion)
- Signed a joint R&D contract with Seoul National University Hospital and Seoul National University Academic-Industrial Cooperation Foundation (NovRD/NovFS (fibrosis, etc.) kidney disease and fibrosis medication development)
- NovAS vascular disease medication) related arteriosclerosis patent application in the US (joint application: NovMetaPharma and VA)
- 2019.02
- NovDB2, NovOB, NovAD reproductive toxicity completed (segment 1, 2) – safety confirmed
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 1 application in 4 countries including the US, Europe, China, and Japan (joint application: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2019.01
- NovRD (liver and kidney medication) related C01 cell protection patent 1 application in 4 countries including the US, Europe, China, and Japan
2018
- 2018.12
- NovDB2, NovOB, NovAD related phase 1 medication completed (Australia) – safety confirmed
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 1 registration in Korea (patent co-owner: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2018.11
- NovOB (anti-obesity medication) related C01 obesity dosage patent application in Korea
- 2018.10
- NovDB2 (type 2 diabetes medication) related CZ compound medication patent application in Korea
- 2018.07
- NovDB2, NovOB, NovAD related phase 1 medication started (Australia)
- NovAD (Alzheimer’s disease medication) related additional US exclusive license secured (worldwide exclusive license or patent right of NovAD established)
- 2018.06
- NovAQ (type 2 diabetes medication) related AQ single medication patent registration in the US (patent co-owner: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2018.03
- Technology Evaluation: Research Institute of Bioscience and Biotechnology: A
eCredible: A
- 2018.02
- NovDB2 (type 2 diabetes medication) clinical phase 2b IRB approval (US FDA)
- 2018.01
- NovWH (antithrombotic and female menopause medication) related female menopause patent application in Korea (joint application: NovMetaPharma and National Development Institute of Korean Medicine)
2017
- 2017.12
- Investment attraction (total of 10 billion)
- NovDB2 (type 2 diabetes medication) clinical phase 2b IND Amend application (US FDA)
- Antithrombotic and female menopause prevention and medication technology transfer (development: National Development Institute of Korean Medicine)
- NovDB2 (type 2 diabetes medication) related C01 diabetes dosage patent application in Korea
- 2017.11
- NovOS (bone loss disease medication) related C01 osteoporosis patent application in Korea
- 2017.10
- NovBH (antithrombotic and female menopause medication) related antithrombotic patent application in Korea (joint application: NovMetaPharma and National Development Institute of Korean Medicine)
- 2017.09
- NovDB2, NovOB, NovAD chronic toxicity test completed (Beagle 39 weeks)
- 2017.08
- Investment attraction (total of 1.8 billion)
- NovAQ (type 2 diabetes medication) related AQ single medication patent application in 4 countries including the US, Europe, China, and Japan
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 1 application in Korea (patent co-owner: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2017.07
- NovRD (liver and kidney medication) related C01 cell protection patent application in Korea
- 2017.05
- NovDB2 (type 2 diabetes medication) and NovOB (anti-obesity medication) related clinical phase 2a medication completed
- 2017.03
- PRO-Z (blood sugar-related health functional food) Chinses health food approval related clinical trial passed
- 2017.02
- NovDB2, NovOB, NovAD chronic toxicity test completed (Rat 26 weeks)
2016
- 2016.10
- NovAQ (type 2 diabetes medication) related AQ single medication patent registration in Korea (patent co-owner: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2016.08
- NovAQ (type 2 diabetes medication) related AQ compound medication patent 1 application in Korea (joint application: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
- 2016.07
- NovAD (Alzheimer’s disease medication) related dopamine AD patent acquisition
- Cell protection composition technology transfer (acquisition of research results commissioned by Chungbuk National University) (NovMetaPharma registered a patent in Korea for NovRD (nephritis medication) in August 2019 through efforts such as self R&D and differentiated patent strategy for this basic technology.)
- 2016.05
- NovDB2 (type 2 diabetes medication) and NovOB (anti-obesity medication) related clinical phase 2a medication started
- 2016.03
- Subsidiary establishment of NovMetaHealth Co., Ltd.
- 2016.02
- NovAQ (type 2 diabetes medication) related AQ single medication patent application in Korea (joint application: NovMetaPharma and Pohang University of Science & Technology Academic-Industrial Cooperation Foundation)
2015
- 2015.12
- Laboratory moved into Pohang Bio Center Research Institute (in Pohang Techno Park)
- Investment attraction (total of 3 billion)
- 2015.11
- HQ relocation (13F, 727 Eonju-ro, Gangnam-gu, Seoul)
- 2015.10
- Listed on KONEX Stock Market
- 2015.09
- Investment attraction (total of 4.9 billion)
- 2015.06
- NovAD (Alzheimer’s disease medication) related CZ, AD basic patent registration in Korea
- 2015.04
- Changed company name to NovMetaPharma Co., Ltd.
2010 ~ 2014
- 2014.12
- Development of new drug substance (for diabetes, anti-obesity, and Alzheimer’s disease medication) production process
- 2014.01
- Laboratory moved into Osong Bio Complex Research Institute
- 2013.12
- Health functional food “PRO-Z Gold" launch in Korea and capital increase (capital KRW 1.49B)
- 2012.03
- Animal testing for the development of type 1 diabetes and osteoporosis medication started
- 2011.05
- Acquired NovOB (anti-obesity medication) related British patent, German patent, and European patent (prostate extract zinc compound) from Dr. Moonki Song for the development of medication and health functional food
- Acquired exclusive licenses for NovDB2 (type 2 diabetes), NovOB (anti-obesity medication), NovAD (Alzheimer’s disease medication), and prostate extract zinc compound (the applicable areas of the rights of the exclusive licenses above are finally expanded from worldwide excluding the US, China, Japan, and Korea as of May 2011, to worldwide excluding the US as of August 2011, and worldwide including the US as of June to July 2018 – excluding some expired patents.)
- 2010.11
- Establishment of PNC MetaPharm
